Epygenix Therapeutics, Inc.
  • HOME
  • WHO WE ARE
  • WHAT WE DO
  • OUR TECHNOLOGY
    • TECHNOLOGY
    • THERAPEUTIC FOCUS
    • DRUG REPURPOSING
  • PIPELINE
  • NEWS
  • CONTACT
  • Search
  • Menu
  • Twitter
  • Mail

https://www.epygenix.com/wp-content/uploads/laban.1296.pdf

Jun 26, 2017/in News /by 3mediaweb
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://www.epygenix.com/wp-content/uploads/logo-new-light-R.1.png 0 0 3mediaweb https://www.epygenix.com/wp-content/uploads/logo-new-light-R.1.png 3mediaweb2017-06-26 15:51:042017-06-26 15:51:04A New School of Drug Discovery

Pages

  • Drug Repurposing
  • Pipelines
  • Technology
  • Therapeutic Focus
  • Who We Are
  • Contact
  • What We Do
  • Our Technology
  • Home
  • News

Categories

  • News

Archive

  • November 2020
  • October 2020
  • September 2020
  • January 2020
  • July 2019
  • June 2019
  • August 2017
  • June 2017
  • April 2017
  • February 2017
  • January 2017

About Epygenix

Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.

How To Find Us

Epygenix Therapeutics
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652

Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
info@epygenix.com

Latest News

  • Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
  • Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
  • Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
  • EpyGenix Launches Phase II Trial for EPX-100
© 2020 Epygenix Therapeutics, Inc. Biotech Web Design"
Profile of Epygenix Therapeutics is listed in June 2017 issue of Biopharma Dealmakers... Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For...
Scroll to top